SOLVEMATE
15.3.2022 09:12:04 CET | Business Wire | Press release
Conversational AI for Customer Service leader Solvemate today announces the addition of multilingual bot management capabilities to its customer service automation platform solution. This platform extension will allow for multiple language chatbot management in a centralized way saving customer service team’s valuable time and effort while maintaining a quality conversational experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220315005132/en/
Customers Expect Great Local Language Experiences
Companies expanding globally cannot afford to forget the post-sales experience. Common Sense Advisory (CSA) Research study found that 75% of customers prefer to buy from companies which provide post-sales support in their native language. Multilingual support adds quality and value to conversations as misunderstandings are minimized and problems can be solved more efficiently.
Scaling Cost Effectively With Multilingual Self Service
It’s often a costly challenge to grow customer service teams across countries and languages. The new Solvemate multilingual chatbot management allows companies to offer the same great self-service experience with highly personalized chatbots to help customers find the answer they are looking for as they scale globally. Automation offers companies the ability to support languages they may not have in their call center or to help mitigate turnover in languages where they struggle to find local language support in certain parts of the world, especially after hours.
Erik Pfannmöller, co-founder and CEO of Solvemate, comments: “Our customers operate in very competitive markets where the nuances of language can affect a brand’s perception. Managing multiple languages across the customer buying journey is a challenge for any company. This new feature will help companies manage the post-sales experience with AI-driven automation and provide a service advantage to help them grow.”
Improve Bot Maintenance Efficiency
The new feature makes it easy for customer service teams to train and maintain their Solvemate chatbot in multiple languages with a centralized and scalable approach.
The benefits include:
- Extend customer service reach
- Improve global self-service rates
- Reduce the complexity of managing multiple language bots
- Control the quality of translations
Aike Alexander Schnug, Customer Care Manager, FOCUS Bikes, comments: “Multilingual chatbots allow us to grow into new markets in a way that builds trust with customers. Solvemate’s new feature enhancement gives us the flexibility to manage each chatbot individually or implement changes across languages which will save our team time and effort.”
Read more about how to boost your customer’s experience with multi-lingual bots .
Learn more at solvemate.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005132/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom